P2Y12 Inhibitors Market
According to Intent Market Research, the P2Y12 Inhibitors Market is expected to grow from USD 242.4 million in 2024-e at a CAGR of 3.7% to touch USD 312.8 million by 2030. The P2Y12 Inhibitors Market is dominated by key players such as AstraZeneca, Bristol-Myers Squibb, Sanofi, Novartis, Johnson & Johnson, AbbVie, Amgen, Mylan Pharmaceuticals, Cardinal Health, Teva Pharmaceutical Industries, F. Hoffmann-La Roche, GSK (GlaxoSmithKline), Boehringer Ingelheim, Eli Lilly, Mitsubishi Tanabe Pharma